Company: PETVW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023398
Chunk: 45

Company: PetVivo Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 45
---
2025, consist of sales of our Spryng® products of $186,902 and PrecisePRP™ products
of $116,382. Revenues in the three months ended September 30, 2024, consisted of sales entirely of our Spryng® products of $200,720.
The increase in our revenues in the three months ended September 30, 2025, compared to the three months ended September 30, 2024, is
due to sales of PrecisePRP™ products, pursuant to our exclusive licensing agreement with VetStem.

Cost
of Sales. Cost of sales were $83,226 and $21,162 for the three months ended September 30, 2025 and 2024, respectively. Cost of
sales includes product costs and labor and overhead related to the sale of our Spryng® products and product costs related to the
sale of PrecisePRP™ products. The increase in our cost of sales in the three months ended September 30, 2025, compared to the three
months ended September 30, 2024, is due to sales of PrecisePRP™ products.

 27 

Operating
Expenses. Operating expenses were $2,285,425 and $2,352,598 for the three months ended September 30, 2025 and 2024, respectively.
The decrease is primarily due to decreased general and administrative (“G&A”) expenses and research and development (“R&D”)
expenses.

General
and administrative (“G&A”) expenses were $1,236,730 and $1,267,117 for the three months ended September 30, 2025 and
2024, respectively. General and administrative expenses include compensation and benefits, contracted services, legal and consulting
fees, and stock compensation expenses.

Sales
and marketing expenses were $787,262 and $620,307 for the three months ended September 30, 2025 and 2024, respectively. Sales and
marketing expenses include compensation, consulting, tradeshows, and stock compensation costs to support the launch of our
Spryng® and the PrecisePRP™ products.

Research
and development (“R&D”) expenses were $261,433 and $465,174 for the three months ended September 30, 2025 and 2024, respectively.
The decrease was primarily related to decreased clinical studies due to tight cash flow constraints.

Operating
Loss. As a result of